You are here: All Products  > Ascentage Starts Trial of MDM2-p53 Inhibitor in Hematologic Malignancies

Ascentage Starts Trial of MDM2-p53 Inhibitor in Hematologic Malignancies

Price: $5.00
Available

Get instant access to this article for unlimited viewing and/or downloading for seven days.